Gelonghui May 17 丨 Microchip Biology (688321europeanblackjack.SH) recently said when receiving a survey from institutional investorseuropeanblackjackAt present, the PTCL indication of Sidabenamide has been included in the national medical insurance for the fourth time, and the DLBCL indication has been approved at the end of April, which meets the conditions for participating in the national medical insurance talks in the second half of this year. New indications will be included in medical insurance. How to maintain drugs through health care negotiationseuropeanblackjackAccessibility and profitability of the company are ongoing efforts of the company. The company expects that the prices of Sidabenamide and sitagliptin sodium will remain relatively stable over the next two years.
